18 completed, 8 recruiting, 6 not yet recruiting, 5 unknown. 45 Phase 1, 19 Phase 2.
Follow irinotecan sucrosofate: new trials by email Literature Review of irinotecan sucrosofate trials Research Report on irinotecan sucrosofate
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Liposomal Irinotecan Plus Cisplatin in Patients With Advanced or Metastatic Solid Malignancies Liposomal Irinotecan Plus Cisplatin - Advanced Solid Malignancies | Phase 1 | Not yet recruiting | National Health Research Institutes, Taiwan | 44 | 2026-12-01 | 2026-11-02 |
| NALIRIFOX (Nal-IRI Plus 5-FU/LV Plus Oxaliplatin) as First-Line Treatment for Patients With Advanced Small Intestine and Appendiceal Cancers Patients will be treated with NALIRIFOX (liposomal irinotecan 50 mg/m2 + 5-FU 2400 mg/m2 + LV 400 mg/m2 + oxaliplatin 60 mg/m2, IV) every 2 weeks for 12 months - Advanced Small Intestine Cancer, Appendiceal Cancers | Phase 1 | Recruiting | The Methodist Hospital Research Institute | 22 | 2026-09-18 | 2026-11-03 |
| Apatinib Combined With Liposomal Irinotecan for Refractory or Metastatic Osteosarcoma Liposomal Irinotecan, Apatinib in arm1 - Osteosarcoma, Osteosarcoma Metastatic | Phase 1 / Phase 2 | Recruiting | Peking University People's Hospital | 56 | 2026-03-05 | 2026-03-18 |
| Intraperitoneal Injection of Liposomal Irinotecan as Monotherapy or in Combination With Recombinant Mutant Human Tumor Necrosis Factor or Bevacizumab for the Treatment of Malignant Ascites Following Failure of Prior Standard Therapy liposomal irinotecan monotherapy, Liposomal Irinotecan + rmhTNF-NC, Liposomal Irinotecan + Bevacizumab - Malignant Ascites | Phase 1 / Phase 2 | Recruiting | Dong sheng Zhang | 48 | 2025-11-28 | 2026-02-09 |
| Nal-IRI (ONIVYDE® ) and Carboplatin in Patients With Advanced or Metastatic GEP-NET nanoliposomal irinotecan plus carboplatin - GEP-NET | Phase 1 / Phase 2 | Enrolling by invitation | National Health Research Institutes, Taiwan | 52 | 2025-08-14 | 2025-08-15 |
| Irinotecan Liposomes Combined with Temozolomide and Vincristine in the Treatment of Pediatric Patients with Solid Tumors Liposomal irinotecan in combination with vincristine and temozolomide - Solid Tumor Cancer | Phase 1 | Not yet recruiting | Yizhuo Zhang | 40 | 2024-12-01 | 2024-11-29 |
| Irinotecan Liposome,Albumin Paclitaxel and Gemcitabine First-line Treatment for Pancreatic Cancer Irinotecan liposome(40mg/m2), Nab-paclitaxel, Gemcitabine - Pancreatic Cancer | Phase 1 / Phase 2 | Not yet recruiting | Harbin Medical University | 132 | 2024-09-01 | 2024-07-22 |
| Exploratory Study of Irinotecan Liposomes in Maintenance Therapy of Metastatic Colorectal Cancer Irinotecan Liposome, Bevacizumab - Metastatic Colorectal Cancer | Phase 1 / Phase 2 | Unknown | West China Hospital | 20 | 2024-08-09 | 2024-08-09 |
| Liposomal Irinotecan + Oxaliplatin + Bevacizumab Versus Liposomal Irinotecan + 5-FU/LV Irinotecan liposoma, oxaliplatin, bevacizumab - Advanced Pancreatic Cancer (Part 1) | Phase 1 / Phase 2 | Recruiting | Dai, Guanghai | 138 | 2024-06-23 | 2025-01-20 |
| Liposomal Irinotecan Plus Bevacizumab in Irinotecan-refractory Metastatic Colorectal Cancer Liposomal irinotecan, Bevacizumab - Colorectal Cancer | Phase 1 / Phase 2 | Unknown | Sun Yat-sen University | 74 | 2024-06-05 | 2024-05-30 |
| Newly Emerging Immunotherapy for Pancreatic Cancer Treatment JS001, JS004, JS007 - Pancreatic Cancer | Phase 1 / Phase 2 | Not yet recruiting | Fudan University | 117 | 2024-04-30 | 2024-04-17 |
| Safety and Efficacy of Adebrelimab Plus Irinotecan Liposome (II) With or Without Famitinib in ES-SCLC Pre-treated With Immunotherapy Adebrelimab, Irinotecan Liposome (II), Adebrelimab, Irinotecan Liposome (II), Famitinib - Extensive-stage Small-cell Lung Cancer | Phase 1 / Phase 2 | Not yet recruiting | Baohui Han | 80 | 2024-04-01 | 2024-03-27 |
| Stereotactic Body Radiation Therapy Followed by NALIRIFOX vs NALIRIFOX for Borderline Resectable Pancreatic Cancer Irinotecan liposome injection, Oxaliplatin, 5-Fluorouracil - Pancreatic Cancer | Phase 1 / Phase 2 | Not yet recruiting | Tianjin Medical University Cancer Institute and Hospital | 96 | 2024-04-01 | 2024-03-15 |
| Ramucirumab (Cyramza), Nal-IRI (ONIVYDE) and Trifluridine/Tipiracil (Lonsurf) in Second Line Metastatic Gastric Cancer . nal-IRI /Experimental, Ramucirumab /Experimental, Trifluridine/Tipiracil /Experimental - Metastatic Gastric Adenocarcinoma, Second Line | Phase 1 / Phase 2 | Recruiting | National Health Research Institutes, Taiwan | 45 | 2024-04-01 | 2026-04-09 |
| Dose Escalation and Expansion Clinical Trial of Irinotecan Liposome Combined With Oxaliplatin and 5-FU/LV Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer Irinotecan Liposome, Oxaliplatin, 5-FU - Metastatic Colorectal Cancer | Phase 1 | Unknown | Shanghai Zhongshan Hospital | 78 | 2024-03-11 | 2024-03-19 |
| Chemotherapy in Patients With Relapsed Small Cell Lung Cancer in Combination With Allopurinol and MycoPhenolate (CLAMP Trial) Mycophenolate Mofetil, Allopurinol, Irinotecan - Small-cell Lung Cancer, Small Cell Lung Carcinoma | Phase 1 | Terminated | Washington University School of Medicine | 17 | 2023-02-27 | 2024-12-05 |
| Intraperitoneal Aerosolized Nanoliposomal Irinotecan (Nal-IRI) in Peritoneal Carcinomatosis From Gastrointestinal Cancer PIPAC with Nal-IRI - Peritoneal Carcinomatosis, Peritoneal Metastases | Phase 1 | Active not recruiting | University Hospital, Ghent | 45 | 2022-11-21 | 2026-07-13 |
| Study of Sotorasib Combined With Chemotherapy for Second Line Treatment of Pancreas Cancer Sotorasib, Liposomal Irinotecan (nal-IRI), 5 Fluorouracil (5FU) - Pancreatic Cancer, Unresectable Pancreatic Cancer | Phase 1 / Phase 2 | Withdrawn | Devalingam Mahalingam | 2022-09-13 | 2023-05-11 | |
| A Study of ASP3082 in Adults With Advanced Solid Tumors Setidegrasib, Cetuximab, Leucovorin - Solid Tumor | Phase 1 | Recruiting | Astellas Pharma Inc | 681 | 2022-06-08 | 2026-10-14 |
| A Study to Compare Onivyde Manufactured at Two Different Production Sites in Adult Participants With Advanced Cancer in the Pancreas Irinotecan liposome injection, Folinic Acid, 5-Fluorouracil - Metastatic Pancreatic Adenocarcinoma | Phase 1 | Completed | Ipsen | 177 | 2022-05-30 | 2025-04-30 |
Showing 20 of 45. Sign in to see all of them.
Pancreatic Neoplasms (11) · Colorectal Neoplasms (9) · Neoplasms (6) · Stomach Neoplasms (4) · Osteosarcoma (3) · Glioblastoma (2) · Glioma (2) · Neuroblastoma (2) · Rhabdomyosarcoma (2) · Sarcoma, Ewing (2) · Small Cell Lung Carcinoma (2) · Adenocarcinoma (1) · Adenocarcinoma, Mucinous (1) · Adenoma, Islet Cell (1) · Appendiceal Neoplasms (1)
National Health Research Institutes, Taiwan (3) · Ipsen (2) · PharmaEngine (2) · University of California, San Francisco (2) · Washington University School of Medicine (2) · Academic and Community Cancer Research United (1) · Andrew Hendifar, MD (1) · Astellas Pharma Inc (1) · Baohui Han (1) · Baylor College of Medicine (1) · Benaroya Research Institute (1) · Brown University (1) · CSPC Ouyi Pharmaceutical Co., Ltd. (1) · Dai, Guanghai (1) · Devalingam Mahalingam (1)
United States (23) · China (10) · Taiwan (4) · France (3) · Spain (2) · Australia (1) · Belgium (1) · Canada (1) · Germany (1) · Hungary (1) · Italy (1) · Japan (1) · Portugal (1) · Puerto Rico (1) · South Korea (1)
Abdullah Esmail, MD (1) · Afsaneh Barzi, MD (1) · Andrew Hendifar, MD (1) · Benoist Chibaudel, MD (1) · Chia-Chi Lin, MD (1) · Daniel Morgensztern, M.D. (1) · Devalingam Mahalingam, MD (1) · Erin K Barr, MD (1) · Georgios Georgakis, MD (1) · Howard Safran, MD (1) · Hui-Jen Tsai, MD, PhD (1) · Jihui Hao, Professor (1) · Joseph Kim, MD (1) · Kian-Huat Lim, M.D, Ph.D. (1)
PMID 27871319, PMID 11230497, PMID 11489791, PMID 11895891, PMID 16271446, PMID 1651156, PMID 17468871, PMID 19349540, PMID 22811849, PMID 23406728, PMID 23880820, PMID 25577133, PMID 26615328, PMID 27091418, PMID 31401903, PMID 33201358, PMID 33284237, PMID 36056179, PMID 36410913, PMID 36734848, PMID 37010988, PMID 39701097, PMID 39746964, PMID 40468090, PMID 41879829
2019 (1), P30CA014089 (1), P30CA015083 (1), R21CA186140 (1), ZIABC011078 (1)